Hayward, CA, United States
Hayward, CA, United States

Time filter

Source Type

News Article | January 12, 2017
Site: www.techtimes.com

CVS has announced that it would sell a generic version of an EpiPen competitor at a far lower price than that of the controversial EpiPen. The nation's largest drugstore chain announced on Thursday that it would sell the generic version of Impax Laboratories' Adrenaclick treatment for life-threatening allergic reactions. CVS' move is apparently a bid to offer consumers a more affordable but safe alternative to Epipen amid the skyrocketing cost of Mylan's controversial epinephrine autoinjector and following Trump lambasting drugmakers on Wednesday, Jan. 11, for the hikes in drug prices. Epipen delivers epinephrine, a synthetic adrenaline that can counter the potentially deadly effects of severe allergic reactions. People suffering from food allergies rely on Epipens for life-saving treatment, but the price of the autoinjector has swollen over the past years, making it too prohibitive for some families. In 2009, a two-pack Epipens costs only around $100, but the price has since skyrocketed to more than $600. In an effort to save, some Americans resorted to using do-it-your-own alternatives that, when used incorrectly, can have serious and even deadly consequences. Mylan, in an effort to appease the public's resentment over the pricey cost of its autoinjector, said that it would start selling a generic version of the EpiPen for $300 per two-pack, which is more than 50 percent cheaper than the price of the regular Epipen. Adrenaclick is a lesser-known epinephrine delivery product that was green-lighted by the Food and Drug Administration in 2003. Regulators do not consider it as an exact copy of the EpiPen, but it contains the same active ingredient found in Mylan's autoinjector. Adrenaclick administers the drug through a slightly different injection. CVS said that it would offer the authorized generic of Adrenaclick two-pack at $109.99 for insured and cash-paying patients without insurance, which means that it would be offered at about 80 percent of the current EpiPen price. The price of generic Adrenaclick remains cheaper even when compared with that of the generic version of EpiPen. Additional cost reductions for the generic Adrenaclick can also be availed by qualified patients who use the coupon programs offered through Impax that would provide a benefit of $100 per pack. "We are thrilled to work with CVS Health to increase access to our low-cost generic Adrenaclick epinephrine auto-injector," said Douglas Boothe, president of Generics Division at Impax Laboratories. "Families need and deserve an affordable option to treat severe allergies." CVS Pharmacy president Helena Foulkes said that Medicaid and Medicare plan members won't qualify for the $100 coupon, but CVS pharmacists will work with customers to determine the cheapest route to acquire the treatment. Foulkes said that the company responded after hearing streams of concern from customers complaining about the price increases of EpiPen. "Our focus has always been on finding solutions for patients first and foremost," Foulkes said. "The best thing that can happen to keep drug prices low is to have a lot of competition in the marketplace." © 2017 Tech Times, All rights reserved. Do not reproduce without permission.


News Article | February 27, 2017
Site: www.prnewswire.com

FORT WASHINGTON, Pa., Feb. 27, 2017 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it plans to participate at the following upcoming investor conferences. Raymond James and Associates' 38th Annual Institutional Investors Conference at 11:35 a.m. ET o...


The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.


The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer, and (b) a decarboxylase inhibitor component.


Patent
Impax Laboratories | Date: 2012-02-06

The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.


Patent
Impax Laboratories | Date: 2015-12-04

The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.


Patent
Impax Laboratories | Date: 2014-11-10

The invention relates to a rapidly disintegrating oral dosage form that contains a drug/polymer solid solution and methods of using the oral dosage form.


The present invention relates to dosage forms of a combination of carbidopa and levodopa comprising both immediate release and controlled release components for the treatment of ailments associated with depleted amounts of dopamine in a patients brain tissue.


News Article | March 1, 2017
Site: www.prnewswire.com

FORT WASHINGTON, Pa., March 1, 2017 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced financial results for the fourth quarter and full year 2016. Fourth Quarter 2016 Total revenues in the fourth quarter of 2016...


NEW YORK, Feb. 15, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Impax Laboratories, Inc. (NASDAQ:...

Loading Impax Laboratories collaborators
Loading Impax Laboratories collaborators